ArticleJournal of registry management2021
Increasing Rates of Colorectal Cancer Among Young People in California, 1988-2017.
Article in Journal of registry management, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) incidence among persons older than 50 years has decreased in California and nationally, but incidence rates have increased among persons younger than 50 years. Previous studies present incidence rates among younger persons using a wide age group of 20-49 years. However, previous population-based studies did not analyze CRC incidence in subgroups defined by age, sex, race/ethnicity, and stage at diagnosis to better understand incidence trends among younger persons. Methods/Approach: We identified all people diagnosed with CRC at the age of 20-49 years from the California Cancer Registry (n = 39,298; 1988-2017). We used SEER*Stat and Joinpoint software to calculate average annual percentage changes (AAPCs) in incidence rates by age at diagnosis, sex, race/ethnicity, and stage. Age was divided into 10-year intervals (20-29, 30-39, and 40-49 years), stage was categorized as early- and late-stage, and race/ethnicity as non-Hispanic White, non-Hispanic Black, Hispanic, Asian/Pacific Islander, and American Indian groups. Results: Statistically significant increases in early-stage CRC incidence rates were observed among the 20-29, 30-39, and 40-49-year age groups in male and female non-Hispanic White populations (AAPC, 6.3%, 3.3%, and 1.9%, respectively) and Hispanic populations (AAPC, 4.9%, 3.5%, and 2.3%, respectively). Statistically significant increases in late-stage CRC incidence rates were observed among all 3 age groups of male and female non-Hispanic White people (AAPC, 2.8%, 3.1%, and 1.7%, respectively) and Hispanic females (AAPC, 4.2%, 2.3%, and 1.1%, respectively). Statistically significant increases in late-stage CRC incidence rates were also seen in the 30-39 and 40-49-year age groups among non-Hispanic White females (AAPC, 3.4% and 1.8%, respectively), Hispanic males (AAPC, 3.6% and 1.6%, respectively), and Asian/Pacific Islander females (AAPC, 1.9% and 0.7%, respectively). Statistically significant increases in late-stage CRC incidence were observed among 40-to 49-year-old Asian/Pacific Islander males (AAPC, 1.4%) and American Indian males and females (AAPC, 5.5%). Conclusion: CRC is increasing among several young age groups. Because evidence suggests that younger adults present with more advanced disease, these results may be useful for educating health care providers about CRC risk and suggest that CRC screening recommendations should be developed for this population. Continued surveillance of CRC incidence rates among young adults is warranted.
Indexed as
Identifiers
37260865PMC10198412W4378953452What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.